ARCHIVES

Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.

This article is from The Cancer Letter archive.

Vol. 30 No. 19 | May 7, 2004

Download PDF Visit The Full Archive

Related Articles

In Brief: General Motors Cancer Research Foundation Prizewinners: Brock, Li, Fraumeni, Harlow

June 16, 1995

In Brief :Three Named to Leadership Posts At St. Jude; Mitchell Weiss Appointed Chair of Hematology

June 11, 2014

RFPs Available, Contract Awards, Sole Source Negotiations

June 25, 1976

Conversation with The Cancer Letter: Pat White: NIH Funding “Our Only Concern”

September 26, 2014

Biotheraputices To Reveal Plans for Expansion

August 8, 1986

Targeted Biopsy More Effective At Selecting Men For Active Surveillance, Study Says

May 30, 2014